See more : HighTide Therapeutics Inc (2511.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pharmiva AB (publ) (PHARM.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmiva AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sagaliam Acquisition Corp. (SAGA) Income Statement Analysis – Financial Results
- Caprock Mining Corp. (CAPR.CN) Income Statement Analysis – Financial Results
- Coxon Precise Industrial Co., Ltd (3607.TW) Income Statement Analysis – Financial Results
- Cords Cable Industries Limited (CORDSCABLE.NS) Income Statement Analysis – Financial Results
- Diversified Energy Company PLC (DECPF) Income Statement Analysis – Financial Results
Pharmiva AB (publ) (PHARM.ST)
About Pharmiva AB (publ)
Pharmiva AB (publ) engages in the research and development of medical products. The company develops Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company is based in Lund, Sweden.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 2.63M | 248.00K | 1.03M | 2.49M |
| Cost of Revenue | 42.00K | -1.97M | 312.00K | -2.83M |
| Gross Profit | 2.59M | 2.21M | 723.00K | 5.32M |
| Gross Profit Ratio | 98.40% | 892.74% | 69.86% | 213.79% |
| Research & Development | 1.26M | 1.12M | 630.00K | 0.00 |
| General & Administrative | 0.00 | 14.57M | 9.63M | 8.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.82M | 14.57M | 9.63M | 8.27M |
| Other Expenses | 26.25M | 8.41M | 4.02M | 4.29M |
| Operating Expenses | 26.25M | 22.98M | 13.65M | 12.55M |
| Cost & Expenses | 26.30M | 21.01M | 13.96M | 9.72M |
| Interest Income | 4.00K | 1.00K | 48.00K | 69.00K |
| Interest Expense | 4.00K | 1.00K | 48.00K | 73.00K |
| Depreciation & Amortization | 1.40M | 1.16M | 666.00K | 780.00K |
| EBITDA | -22.27M | -19.60M | -13.29M | -8.95M |
| EBITDA Ratio | -847.34% | -7,904.03% | -1,284.25% | -359.67% |
| Operating Income | -23.67M | -20.76M | -13.96M | -9.73M |
| Operating Income Ratio | -900.61% | -8,371.77% | -1,348.60% | -391.03% |
| Total Other Income/Expenses | -4.00K | -1.00K | -48.00K | 1.25M |
| Income Before Tax | -23.67M | -20.76M | -14.01M | -9.80M |
| Income Before Tax Ratio | -900.76% | -8,372.18% | -1,353.24% | -393.97% |
| Income Tax Expense | 4.00K | 1.00K | 48.00K | 73.00K |
| Net Income | -23.68M | -20.76M | -14.05M | -9.87M |
| Net Income Ratio | -900.91% | -8,372.58% | -1,357.88% | -396.90% |
| EPS | -1.36 | -2.80 | -1.75 | -1.23 |
| EPS Diluted | -1.36 | -2.80 | -1.75 | -1.23 |
| Weighted Avg Shares Out | 17.38M | 7.41M | 8.03M | 8.03M |
| Weighted Avg Shares Out (Dil) | 17.38M | 7.41M | 8.03M | 8.03M |
No news found for: PHARM.ST
Source: https://incomestatements.info
Category: Stock Reports